We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.625 | 5.15% | 12.75 | 12.50 | 13.00 | 13.75 | 12.25 | 12.25 | 2,529,497 | 16:24:33 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -7.82 | 22.19M |
Date | Subject | Author | Discuss |
---|---|---|---|
04/10/2017 09:30 | This video interview clarifies the RNS in a nutshell making good progress and expect more of the same. “SkinBioTherap | bobalot | |
03/10/2017 18:51 | I suspect the key here is similar to OPTI - Peeps need to know as much about themselves as they do their chosen investment. Point being, you are either a trader constantly price watching and spooking yourself, or you're a long term investor building a decent position ahead of commercial traction and then revenues. Of course it help as each risk obstacle is removed as several were in today's update. We must accept we are probably 2 years away from even a hint of revenues, but SBTX has the cash to see it through. | elrico | |
03/10/2017 18:35 | New SBTX video released today - Proactive Investors Stocktube interview with Dr O'Neill. "SkinBioTherapeutics sees flagship technology take critical next step" Dr Catherine O'Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), updates Proactive on progress with their platform - saying it's passed a key safety test. | bdog51 | |
03/10/2017 17:54 | Great article: SkinBioTherapeutics PLC technology passes crucial milestone after independent test 07:54 03 Oct 2017 Its SkinBiotix cream was assessed for cellular toxicity Its SkinBiotix cream is being developed as a cosmetic initially, though it has potential medical uses too SkinBioTherapeutics PLC (LON:SBTX) said its flagship technology had passed a key safety test as it updated on progress. Its SkinBiotix cream was assessed for cellular toxicity and specifically for adverse biological reactions from mammalian cell cultures. READ: SkinBioTherapeutics - New listing in the emerging field of the human microbiome has multiple value trigger points SkinBio said no cytotoxicity was observed; in other words there was no malformation of cells, or cell degeneration. The data backed up in-house results compiled by the company, which listed on the stock market in April. “This was one of the key milestones to pass and was highlighted as such at the IPO,” said chief executive, Dr Catherine O’Neill. “Its passing marks a critical step in our progression and the transitioning of the technology into human validation studies.” Patents The SkinBiotix platform is protected by three patent families and 18 patent applications and is supported by a host of peer-reviewed academic publications and has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration. From that it is developing three products that manage, protect and restore the body’s largest organ. READ: SkinBioTh First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next. Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections. The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment. The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes. Three phases Pilot formulation has begun with an outside partner with expertise in cosmetics. Phase one of three is complete: testing the solubility and preservative requirements of the technology. Phase two, identifying a final blend for testing, is currently underway. At the same time, a study has determined the cream is best applied every five hours for protection against infection. In the update, SkinBioTherapeutics said it had finalised a dosing level at which the technology will be used which maintains the viability of the skin cells. It has also received confirmation of the modifying property of SkinBiotix on the protein composition of the skin, increasing the expression of a protein called Claudin 4 that help protect the skin. Early-stage commercial discussions have also begun with both would-be licensees and manufacturers. "Operationally, we are on track,” said CEO O’Neill. “The development programmes are progressing well, we are generating further scientific data on SkinBiotix confirming its suitability for application to skin, and industry awareness of our technology is growing." www.proactiveinvesto | bobalot | |
03/10/2017 15:26 | Most likely very low cash burn....given there are only four employees. | bobalot | |
03/10/2017 15:08 | Stranger things, destiny; maybe share price will move North on Thursday. Odds? | owenmo | |
03/10/2017 14:44 | thats it its shot its load no more news for 18 months now comes 5p | destinybagoshite | |
03/10/2017 14:39 | That's all of Thursday's good news done and dusted and accounted for, and share price moves South. Now we're left with the rest of the story-to-date, as in cash spend thus far. Oi veh! | owenmo | |
03/10/2017 10:44 | Risky, this is exactly what SoH said to me at the investor evening. SBTX are using a different agency to OPTI (could be Charles River?) their approach to updates is different, much more Pharma style, in that it's less frequent but more substantive. Fwiw SoH prefers the OPTI approach, he feels it's important to keep investors updated of progress on. Frequent basis. I'm with him ;0) | trotterstrading | |
03/10/2017 09:32 | I think that it was Elrico who said that they don't want to put out loads of RNSs, but that the ones they do will be powerful. That certainly seems to be the case here. John | 2350220 | |
03/10/2017 08:50 | HERE IS A CLUE about who is interested in the technology, taken from their August 14th article. Big pharmaceutical companies interested in the microbiome field include Merck & Co. Inc., Pfizer Inc. and J ALL HUGE MULTI NATIONALS. | bobalot | |
03/10/2017 08:44 | I find it strange we have all this news in one. We have at least three separate RNS's within this mornings news: 1. The toxicity tests results. 2. Manufacturing scale up confirmed with external partner (would be very interesting to know who this is) 3. Confirmation of the modifying property of skinbiotix on the protein composition of skin. I find it hard to believe this has all happened this week which means they have been sitting on news. Surely they should be updating shareholders as and when. | riskybusiness1 | |
03/10/2017 08:42 | The basic model has passed health and safety tests --- clinical trials are next by the looks of development ---- EXCELLENT PROGRESS IMO. SkinBioTherapeutics plc SkinBiotix(R) platform passes external cytotoxicity tests Scientific progress on track Manchester, UK - 3 October 2017 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, has passed third party cellular toxicity tests for its SkinBiotix(R) technology, confirming previous in-house observations on its safety and applicability. The Company has also been progressing its three programmes and is on track to hit its key milestone of first studies in man in 2018. Cytotoxicity studies The studies were conducted by Charles River, a Contract Research Organisation, in accordance with the OECD Principles of Good Laboratory Practice. The objective of the toxicity tests was to determine if there were any adverse biological reactions from mammalian cell cultures following the use of SkinBioTherapeutics' SkinBiotix(R) technology. Following incubation for 24 hours, no cytotoxicity was observed e.g., malformation of cells or cell degeneration. The data confirm SkinBioTherapeutics' in-house observations on how mammalian skin cells and fibroblasts respond to being exposed to SkinBiotix(R). This further supports the principle of SkinBiotix(R)'s suitability for use in skin care applications. Two further tests, phototoxicity and in vitro ocular toxicity are scheduled. These results will be reported when the data is received. Scientific update As outlined at IPO in April 2017, SkinBioTherapeutics has been concentrating on further developing its technology towards the three applications in skin care, anti-infection and skin repair. The positive cytotoxicity result above is a key milestone. However, other work is progressing well and the Company has summarised this below: - Manufacture: work on scale-up has been initiated, confirmed by the successful manufacture of SkinBiotix(R) by an external partner - Pilot scale formulation has been initiated by an external partner with expertise in cosmetic formulation development. Phase one of three is complete; testing of solubility and preservative requirements of the technology. Phase two, identifying a final blend for testing, is currently underway - Early stage commercial discussions are ongoing with both potential manufacturing partners as well as potential licensees - Anti-infection and eczema programmes o A 'time-course' study, has confirmed that the frequency of application required for protection is three times daily. Therefore, protection against Staphylococcus aureus infection for both eczema and infection programmes requires application every five hours* - Regulatory process has commenced and a regulatory consultant has been appointed - Ongoing scientific studies: o Defining dosage is complete - for all three applications. SkinBioTherapeutics has finalised a dosing level at which the technology will be used which maintains the viability of the skin cells o Confirmation of the modifying property of SkinBiotix(R) on protein composition of the skin, increasing the expression of Claudin 4, an essential component in tight junctions which are critical for the barrier characteristic of skin *These data were recently presented at a Wellcome Trust conference: "Host Microbiome Interactions in Health and Disease". Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented: "This announcement demonstrates the excellent progress SkinBioTherapeutics is making at all levels - scientific, development, manufacture and commercial. "The result from the cytotoxicity testing by Charles River is essential external validation of our SkinBiotix(R) platform. This was one of the key milestones to pass and was highlighted as such at the IPO. Its passing marks a critical step in our progression and the transitioning of the technology into human validation studies. "Operationally, we are on track. The development programmes are progressing well, we are generating further scientific data on SkinBiotix(R) confirming its suitability for application to skin, and industry awareness of our technology is growing." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. -Ends- | bobalot | |
03/10/2017 08:23 | A fully sensible argument shazbo. I'm already fully loaded and will just have to sit on my hands. It's some comfort not being 30% down at least! John | 2350220 | |
03/10/2017 07:59 | Totally agree with you Ferdinand, great progress made no doubt, but have we learned nothing from Opti? Getting the product right takes time, replicating in industrial quantities takes time, negotiating with partners takes time, contracts take time, getting products on shelves takes time, sales working their way through to the bottom line takes time. Analysts, IIs, Brokers, big time PIs all want to see the £££ | shazbo | |
03/10/2017 07:23 | IMO company significantly de-riskes based on RNS. Announcement will have little impact on price but lays strong foundation for future growth. Time to buy is now. | vanduke | |
03/10/2017 07:20 | Early in the day and this news will hopefully be posted elsewhere. It is a good update and buyers may well appear later today. | rafboy | |
03/10/2017 07:12 | I agree that the progress made is excellent. My point was that I doubt it will move the share price as it's all 'expected progress' as Cath states herself. Only when we get a news of human trials success and steps to commercialisation do I expect a real uplift....and what an uplift it will be! I hope like everyone else that the price rises as I am a holder of both OPTI and SBTX | f3rdinand | |
03/10/2017 07:00 | very happy with SBTX RNS hugely derisked now. Incredible achievement for SoH and SBTX team every platform derisked scientifically | trotterstrading | |
03/10/2017 06:53 | Oh god! Every thread seems to have a troll these days | trotterstrading | |
03/10/2017 06:48 | Albany are you short? Think you need to do some proper research. | rafboy | |
03/10/2017 06:40 | I WOULDNT BECAUSE IT IS BURNING CASH TOO FAST BUT THEN VANDUKE LOOKS LIKE A PLANT AS HE ONLY POSTS ON THIS AND OPTI MAYBE A DIRECTOR | albanyvillas | |
03/10/2017 06:30 | Based on today's RNS I will be buying. | vanduke | |
03/10/2017 06:28 | All on track is exactly what we want right now. Good to see we are already talking with commercial partners. | rafboy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions